New combo radiation aims to cut prostate cancer treatment time

NCT ID NCT06817668

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 42 times

Summary

This study is testing whether a new, shorter course of radiation therapy is safe and tolerable for men with unfavorable or higher-risk prostate cancer. It combines external beam radiation with a single internal radiation boost (brachytherapy). The trial will enroll 31 participants and monitor side effects for 3 months after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    RECRUITING

    Indianapolis, Indiana, 46202, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Radiation therapy (external beam and internal brachytherapy)

What this could lead to

If successful, this could offer a shorter, more convenient radiation treatment option for men with higher-risk prostate cancer.

What could go wrong

This is a small, early-phase study (31 people) focused on safety, not effectiveness. The combination may cause more side effects than standard radiation.

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.